Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

Antonio Jimeno, Gurulingappa Hallur, Audrey Chan, Xiangfeng Zhang, George Cusatis, Fonda Chan, Preeti Shah, Rongbing Chen, Ernest Hamel, Elizabeth Garrett-Mayer, Saeed Khan, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

In this work, we evaluated two lead compounds, referred to as SG410 and SG430, obtained from a screen of sulfur benzoylphenylurea analogues, against in vitro and in vivo models of pancreas cancer. Both drugs showed a similar mechanism of action profile, with SG410 being more potent as an inhibitor of tubulin assembly. We determined the best in vivo administration schedule and tested SG410 and SG430 in nine cases of a novel platform of direct pancreas cancer xenografts. Both compounds had antiproliferative activity in vitro in the low nanomolar range, but only SG410 showed significant activity in vivo. Administration of SG410 resulted in significant tumor growth delay in five of nine groups tested. In a direct comparison in three of the cases, SG410 was at least as efficacious as docetaxel. We also sought markers that would be predictive of the efficacy of these agents, and we found such a marker in microtubule-associated protein tau (MAPT). This protein enhances the assembly and stability of microtubules. In both the cell lines and the direct human xenografts, MAPT mRNA and protein levels correlated well. There was also a statistically significant inverse correlation between MAPT expression and sensitivity to the tested agents. In summary, the novel sulfur benzoylphenylurea SG410 showed activity inversely related to MAPT expression in a preclinical model of pancreatic cancer comparable with that observed with docetaxel, another microtubule-targeting agent.

Original languageEnglish (US)
Pages (from-to)1509-1516
Number of pages8
JournalMolecular Cancer Therapeutics
Volume6
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

docetaxel
Microtubule-Associated Proteins
Pancreatic Neoplasms
Sulfur
Heterografts
Microtubules
Tubulin Modulators
tau Proteins
Appointments and Schedules
Cell Line
Messenger RNA
Growth
Pharmaceutical Preparations
Neoplasms
Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. / Jimeno, Antonio; Hallur, Gurulingappa; Chan, Audrey; Zhang, Xiangfeng; Cusatis, George; Chan, Fonda; Shah, Preeti; Chen, Rongbing; Hamel, Ernest; Garrett-Mayer, Elizabeth; Khan, Saeed; Hidalgo, Manuel.

In: Molecular Cancer Therapeutics, Vol. 6, No. 5, 01.05.2007, p. 1509-1516.

Research output: Contribution to journalArticle

Jimeno, A, Hallur, G, Chan, A, Zhang, X, Cusatis, G, Chan, F, Shah, P, Chen, R, Hamel, E, Garrett-Mayer, E, Khan, S & Hidalgo, M 2007, 'Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer', Molecular Cancer Therapeutics, vol. 6, no. 5, pp. 1509-1516. https://doi.org/10.1158/1535-7163.MCT-06-0592
Jimeno, Antonio ; Hallur, Gurulingappa ; Chan, Audrey ; Zhang, Xiangfeng ; Cusatis, George ; Chan, Fonda ; Shah, Preeti ; Chen, Rongbing ; Hamel, Ernest ; Garrett-Mayer, Elizabeth ; Khan, Saeed ; Hidalgo, Manuel. / Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 5. pp. 1509-1516.
@article{a62f04e853214855b31601560fa28deb,
title = "Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer",
abstract = "In this work, we evaluated two lead compounds, referred to as SG410 and SG430, obtained from a screen of sulfur benzoylphenylurea analogues, against in vitro and in vivo models of pancreas cancer. Both drugs showed a similar mechanism of action profile, with SG410 being more potent as an inhibitor of tubulin assembly. We determined the best in vivo administration schedule and tested SG410 and SG430 in nine cases of a novel platform of direct pancreas cancer xenografts. Both compounds had antiproliferative activity in vitro in the low nanomolar range, but only SG410 showed significant activity in vivo. Administration of SG410 resulted in significant tumor growth delay in five of nine groups tested. In a direct comparison in three of the cases, SG410 was at least as efficacious as docetaxel. We also sought markers that would be predictive of the efficacy of these agents, and we found such a marker in microtubule-associated protein tau (MAPT). This protein enhances the assembly and stability of microtubules. In both the cell lines and the direct human xenografts, MAPT mRNA and protein levels correlated well. There was also a statistically significant inverse correlation between MAPT expression and sensitivity to the tested agents. In summary, the novel sulfur benzoylphenylurea SG410 showed activity inversely related to MAPT expression in a preclinical model of pancreatic cancer comparable with that observed with docetaxel, another microtubule-targeting agent.",
author = "Antonio Jimeno and Gurulingappa Hallur and Audrey Chan and Xiangfeng Zhang and George Cusatis and Fonda Chan and Preeti Shah and Rongbing Chen and Ernest Hamel and Elizabeth Garrett-Mayer and Saeed Khan and Manuel Hidalgo",
year = "2007",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0592",
language = "English (US)",
volume = "6",
pages = "1509--1516",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

AU - Jimeno, Antonio

AU - Hallur, Gurulingappa

AU - Chan, Audrey

AU - Zhang, Xiangfeng

AU - Cusatis, George

AU - Chan, Fonda

AU - Shah, Preeti

AU - Chen, Rongbing

AU - Hamel, Ernest

AU - Garrett-Mayer, Elizabeth

AU - Khan, Saeed

AU - Hidalgo, Manuel

PY - 2007/5/1

Y1 - 2007/5/1

N2 - In this work, we evaluated two lead compounds, referred to as SG410 and SG430, obtained from a screen of sulfur benzoylphenylurea analogues, against in vitro and in vivo models of pancreas cancer. Both drugs showed a similar mechanism of action profile, with SG410 being more potent as an inhibitor of tubulin assembly. We determined the best in vivo administration schedule and tested SG410 and SG430 in nine cases of a novel platform of direct pancreas cancer xenografts. Both compounds had antiproliferative activity in vitro in the low nanomolar range, but only SG410 showed significant activity in vivo. Administration of SG410 resulted in significant tumor growth delay in five of nine groups tested. In a direct comparison in three of the cases, SG410 was at least as efficacious as docetaxel. We also sought markers that would be predictive of the efficacy of these agents, and we found such a marker in microtubule-associated protein tau (MAPT). This protein enhances the assembly and stability of microtubules. In both the cell lines and the direct human xenografts, MAPT mRNA and protein levels correlated well. There was also a statistically significant inverse correlation between MAPT expression and sensitivity to the tested agents. In summary, the novel sulfur benzoylphenylurea SG410 showed activity inversely related to MAPT expression in a preclinical model of pancreatic cancer comparable with that observed with docetaxel, another microtubule-targeting agent.

AB - In this work, we evaluated two lead compounds, referred to as SG410 and SG430, obtained from a screen of sulfur benzoylphenylurea analogues, against in vitro and in vivo models of pancreas cancer. Both drugs showed a similar mechanism of action profile, with SG410 being more potent as an inhibitor of tubulin assembly. We determined the best in vivo administration schedule and tested SG410 and SG430 in nine cases of a novel platform of direct pancreas cancer xenografts. Both compounds had antiproliferative activity in vitro in the low nanomolar range, but only SG410 showed significant activity in vivo. Administration of SG410 resulted in significant tumor growth delay in five of nine groups tested. In a direct comparison in three of the cases, SG410 was at least as efficacious as docetaxel. We also sought markers that would be predictive of the efficacy of these agents, and we found such a marker in microtubule-associated protein tau (MAPT). This protein enhances the assembly and stability of microtubules. In both the cell lines and the direct human xenografts, MAPT mRNA and protein levels correlated well. There was also a statistically significant inverse correlation between MAPT expression and sensitivity to the tested agents. In summary, the novel sulfur benzoylphenylurea SG410 showed activity inversely related to MAPT expression in a preclinical model of pancreatic cancer comparable with that observed with docetaxel, another microtubule-targeting agent.

UR - http://www.scopus.com/inward/record.url?scp=34250705854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250705854&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0592

DO - 10.1158/1535-7163.MCT-06-0592

M3 - Article

VL - 6

SP - 1509

EP - 1516

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -